The study explored the therapeutic potential of induced pluripotent stem cell-derived CD146+ mesenchymal stem cells (CD146+iMSCs) for treating ulcerative colitis (UC). These stem cells were compared to CD146+ umbilical cord mesenchymal stem cells (UCMSCs) in terms of biological traits, anti-inflammatory effects, and immune modulation mechanisms.
The study explored the therapeutic potential of induced pluripotent stem cell-derived CD146+ mesenchymal stem cells (CD146+iMSCs) for treating ulcerative colitis (UC). These stem cells were compared to CD146+ umbilical cord mesenchymal stem cells (UCMSCs) in terms of biological traits, anti-inflammatory effects, and immune modulation mechanisms.
CD146+iMSCs demonstrated stronger proliferation, self-renewal, and differentiation abilities, maintaining classical mesenchymal stem cell markers. They effectively shifted macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, showing superior immune modulation compared to CD146+UCMSCs. Transcriptome analysis revealed that CD146+iMSCs upregulated pathways involved in calcium signaling, TGF-β, and immune regulation, while suppressing TNF signaling, enhancing their anti-inflammatory activity.
In a UC mouse model, CD146+iMSCs significantly alleviated symptoms, reduced weight loss, restored colon length, repaired intestinal barriers, and improved mucosal architecture. They reduced inflammatory cytokines (IL-6, TNF-α, IL-1β) and normalized immune cell populations, restoring immune homeostasis. The study identified the suppression of the IL-17 signaling pathway as a critical mechanism for UC treatment. Additionally, nine key inflammatory hub genes were downregulated by CD146+iMSCs, further supporting their anti-inflammatory effects.
CD146+iMSCs also regulated the cGAS-STING pathway, promoting immune tolerance and enhancing mucosal healing. Their regenerative effects were linked to genes involved in tissue repair (TGFB2, CXCL12, VEGF, FGF). Intraperitoneal injection provided better therapeutic outcomes by improving biodistribution to inflamed sites.
Overall, CD146+iMSCs demonstrated robust regenerative, anti-inflammatory, and immunomodulatory potential, offering a promising therapy for UC through immune regulation and tissue repair mechanisms.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.